These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31534543)

  • 61. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer.
    Yang YC; Pan KF; Lee WJ; Chang JH; Tan P; Gu CC; Chang WM; Yang SF; Hsiao M; Hua KT; Chien MH
    Cancer Res; 2020 Aug; 80(16):3292-3304. PubMed ID: 32561533
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
    Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
    Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
    Lypova N; Telang S; Chesney J; Imbert-Fernandez Y
    J Biol Chem; 2019 Jul; 294(27):10530-10543. PubMed ID: 31126985
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
    Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
    Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
    Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
    [TBL] [Abstract][Full Text] [Related]  

  • 67. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sulforaphane attenuates EGFR signaling in NSCLC cells.
    Chen CY; Yu ZY; Chuang YS; Huang RM; Wang TC
    J Biomed Sci; 2015 Jun; 22(1):38. PubMed ID: 26036303
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Structure-Guided Strategies of Targeted Therapies for Patients with
    Du Z; Sun J; Zhang Y; Hesilaiti N; Xia Q; Cui H; Fan N; Xu X
    Biomolecules; 2023 Jan; 13(2):. PubMed ID: 36830579
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma.
    Makinoshima H; Takita M; Matsumoto S; Yagishita A; Owada S; Esumi H; Tsuchihara K
    J Biol Chem; 2014 Jul; 289(30):20813-23. PubMed ID: 24928511
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.
    Yang Z; Tam KY
    Int J Biol Sci; 2018; 14(2):204-216. PubMed ID: 29483838
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PKCĪ“-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs.
    Chen CH; Wang BW; Hsiao YC; Wu CY; Cheng FJ; Hsia TC; Chen CY; Wang Y; Weihua Z; Chou RH; Tang CH; Chen YJ; Wei YL; Hsu JL; Tu CY; Hung MC; Huang WC
    Oncogene; 2021 Jul; 40(29):4796-4808. PubMed ID: 34155348
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer.
    Luo Y; Yang Y; Peng P; Zhan J; Wang Z; Zhu Z; Zhang Z; Liu L; Fang W; Zhang L
    Transl Lung Cancer Res; 2021 Jan; 10(1):128-142. PubMed ID: 33569299
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells.
    Yin L; Zhang Y; Yin L; Ou Y; Lewis MS; Wang R; Zhau HE; Zhou Q; Chung LWK
    Mol Cancer Ther; 2021 Dec; 20(12):2527-2538. PubMed ID: 34583981
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines.
    Li J; Pan YY; Zhang Y
    Oncol Lett; 2013 Feb; 5(2):440-446. PubMed ID: 23420122
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cell membrane based biomimetic nanocomposites for targeted therapy of drug resistant EGFR-mutated lung cancer.
    Wu P; Yin D; Liu J; Zhou H; Guo M; Liu J; Liu Y; Wang X; Liu Y; Chen C
    Nanoscale; 2019 Nov; 11(41):19520-19528. PubMed ID: 31573595
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma.
    Jeong HO; Lee H; Kim H; Jang J; Kim S; Hwang T; Choi DW; Kim HS; Lee N; Lee YM; Park S; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee S; Lee SH
    iScience; 2022 Nov; 25(11):105358. PubMed ID: 36339256
    [TBL] [Abstract][Full Text] [Related]  

  • 80. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.
    Kuang R; Jahangiri A; Mascharak S; Nguyen A; Chandra A; Flanigan PM; Yagnik G; Wagner JR; De Lay M; Carrera D; Castro BA; Hayes J; Sidorov M; Garcia JLI; Eriksson P; Ronen S; Phillips J; Molinaro A; Koliwad S; Aghi MK
    JCI Insight; 2017 Jan; 2(2):e88815. PubMed ID: 28138554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.